2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)

This is not a test of a single intervention. The guideline is a systematic review of the entire evidence base for SVT management, covering:

**Diagnostic methods:** 12-lead ECG, Holter monitoring, event recorders, electrophysiological study (EPS)

**Acute termination manoeuvres:** Vagal manoeuvres (Valsalva, carotid sinus massage), intravenous adenosine, intravenous verapamil/diltiazem, electrical cardioversion

**Long-term management:** Catheter ablation (radiofrequency or cryoablation), antiarrhythmic drugs (flecainide, propafenone, beta-blockers, calcium channel blockers), and lifestyle modification

**Outcome measures:** Termination of tachycardia, recurrence rate, symptom burden, quality of life, complication rates (e.g., stroke, heart failure, death)

The guideline does not provide a single effect size for any intervention because it aggregates data from hundreds of studies. For example, catheter ablation for typical atrioventricular nodal reentrant tachycardia (AVNRT) has a success rate of 95–98% with a 1–3% risk of complete heart block requiring a pacemaker.

The guideline covers all adult patients with SVT, defined as tachycardias originating above the ventricles (atria or AV node). Specific populations include:

**General adult population:** Incidence of SVT is approximately 35 per 100,000 person-years, with a prevalence of 2.25 per 1000 people

**Women:** SVT is more common in women (2:1 ratio for AVNRT), and pregnancy can increase episode frequency

**Athletes:** SVT can be triggered by exercise, but most athletes with SVT have no structural heart disease

**Elderly:** SVT incidence increases with age, and ablation success rates remain high (>90%) but complication rates are slightly higher

**Patients with structural heart disease:** SVT can coexist with coronary artery disease, heart failure, or valvular disease, which changes drug choices (e.g., flecainide is contraindicated in ischaemic heart disease)

The guideline does not include children (separate paediatric guidelines exist) or patients with atrial fibrillation (AF) or atrial flutter (separate guidelines).

The guideline does not use a single measurement instrument. Instead, it evaluates studies that used:

**Electrocardiography (ECG):** 12-lead ECG during tachycardia to classify SVT type (AVNRT, AVRT, atrial tachycardia, etc.)

**Holter monitoring:** 24–48 hour continuous ECG to capture spontaneous episodes

**Event recorders:** Patient-activated or auto-triggered devices worn for days to weeks to capture infrequent episodes

**Electrophysiological study (EPS):** Invasive catheter-based mapping of cardiac electrical pathways to confirm diagnosis and guide ablation

**Symptom diaries:** Patient-reported frequency, duration, and severity of palpitations, dizziness, syncope, chest pain, and dyspnoea

**Quality of life questionnaires:** SF-36, EQ-5D, or disease-specific tools like the Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia (ASTA)

For self-experimenters, the most relevant measurement is a symptom diary with a 1–10 severity scale and a heart rate monitor (e.g., Polar H10 chest strap or Apple Watch) to capture episode onset and termination.

**Study design:** This is a clinical practice guideline, not a primary study. The Task Force used a systematic review methodology: they searched MEDLINE, EMBASE, and the Cochrane Library for studies published up to 2018, graded the quality of evidence using the GRADE system (Grades of Recommendation, Assessment, Development, and Evaluation), and formulated recommendations with levels of evidence (Class I = recommended, Class IIa = should be considered, Class IIb = may be considered, Class III = not recommended).

**Key design features:**

**No randomisation or blinding:** The guideline aggregates data from RCTs, observational studies, case series, and expert opinion. The highest-quality evidence comes from RCTs of catheter ablation vs. antiarrhythmic drugs, but many recommendations are based on observational data or consensus.

**Duration:** The evidence spans decades, from the 1980s to 2018. The guideline itself was developed over 2 years (2017–2019).

**Statistical approach:** Meta-analyses were performed where possible, but most recommendations are based on pooled event rates (e.g., ablation success rates of 95% with 95% confidence intervals of 92–98%).

**What this design can and cannot prove:**

**Can prove:** That certain interventions (e.g., catheter ablation for AVNRT) have high success rates and low complication rates in large populations. That vagal manoeuvres terminate SVT in ~20–50% of cases. That antiarrhythmic drugs reduce recurrence rates by ~50–70% compared to placebo.

**Cannot prove:** That any single intervention works for you personally. Guidelines are population-level averages — your individual response to vagal manoeuvres, drugs, or ablation may differ. The guideline also cannot prove causality for lifestyle triggers (e.g., caffeine, alcohol, stress) because the evidence is mostly observational and confounded.

**Major methodological weaknesses:**

**Publication bias:** Studies with positive results are more likely to be published, especially for ablation and drug trials.

**Heterogeneity:** Studies use different definitions of SVT, different ablation techniques, and different follow-up durations (6 months to 5 years).

**Industry funding:** Many drug and ablation device trials are funded by pharmaceutical or device companies, though the guideline authors declared conflicts of interest.

**Lack of long-term data:** Most ablation studies have 1–3 year follow-up; data beyond 5 years are sparse.

**No individual-level data:** The guideline cannot tell you how your age, sex, comorbidities, or lifestyle affect your personal risk or response.

The guideline makes 127 specific recommendations. The most important for a self-experimenter are:

**Diagnosis:**

A 12-lead ECG during tachycardia is the gold standard for diagnosis (Class I recommendation, level of evidence B)

Holter monitoring (24–48 h) captures SVT in ~20–30% of patients with daily symptoms; event recorders (2–4 weeks) capture episodes in ~60–80% of patients with weekly symptoms

Electrophysiological study is recommended when ECG diagnosis is unclear or ablation is planned (Class I, level of evidence B)

**Acute termination:**

Vagal manoeuvres (Valsalva, carotid sinus massage) terminate SVT in 20–50% of cases (Class I, level of evidence B). The modified Valsalva (bearing down while lying supine with legs raised) has a higher success rate (~43%) than standard Valsalva (~17%) in one RCT (n=214, p<0.001)

Intravenous adenosine terminates SVT in 90–95% of cases within 30–60 seconds (Class I, level of evidence A). Side effects (chest pain, dyspnoea, flushing) occur in ~30% but are transient

Intravenous verapamil or diltiazem terminates SVT in 80–90% of cases within 2–5 minutes (Class I, level of evidence A), but carries a risk of hypotension and bradycardia

**Long-term management:**

Catheter ablation is first-line therapy for symptomatic, recurrent SVT (Class I, level of evidence A). Success rates: AVNRT 95–98%, AVRT (Wolff-Parkinson-White) 95–97%, atrial tachycardia 80–90%. Major complication rate (cardiac tamponade, stroke, death) is <1% in experienced centres

Antiarrhythmic drugs (flecainide, propafenone, beta-blockers, calcium channel blockers) reduce recurrence by 50–70% compared to placebo, but 30–50% of patients discontinue due to side effects or lack of efficacy (Class IIa, level of evidence B)

For patients with infrequent, well-tolerated episodes, no treatment (observation only) is reasonable (Class IIa, level of evidence C)

**Lifestyle and triggers:**

Caffeine, alcohol, and stress are commonly reported triggers, but the evidence is weak (observational studies, no RCTs). One study (n=100) found that 60% of patients reported caffeine as a trigger, but only 20% had a reproducible response on provocation testing

Exercise can trigger SVT in some patients, but regular exercise is not contraindicated (Class I, level of evidence C)

Translating the population-level data into plain English:

**Vagal manoeuvres:** If you have an SVT episode, a well-performed Valsalva (bearing down for 15 seconds while lying down with legs raised) will terminate it about 4 out of 10 times. That is roughly equivalent to the success rate of a single dose of a beta-blocker taken at the onset of symptoms.

**Adenosine:** If you go to the emergency department and receive intravenous adenosine, your SVT will stop within 30 seconds 9 out of 10 times. The sensation is often described as "being hit by a truck" — intense chest pressure, flushing, and a feeling of doom that lasts 10–20 seconds.

**Catheter ablation:** If you undergo ablation for AVNRT, you have a 96% chance of being episode-free at 1 year. That is equivalent to a cure for most people, though 2–5% may have a recurrence within 5 years.

**Drugs:** Taking a daily beta-blocker (e.g., metoprolol 25–50 mg) reduces your episode frequency by about half — from, say, 2 episodes per week to 1 episode per week. But you may also feel fatigued, cold hands, and reduced exercise tolerance.

**Lifestyle triggers:** The effect of caffeine is highly individual. For some people, one cup of coffee triggers an episode; for others, 5 cups have no effect. The guideline cannot give a single number because the evidence is too weak.

**What the authors acknowledge:**

Many recommendations are based on low-quality evidence (observational studies or expert opinion) — only ~30% of recommendations are supported by RCTs

The guideline does not cover paediatric patients, pregnant women (except a brief section), or patients with atrial fibrillation/flutter

The evidence for lifestyle modification (caffeine, alcohol, stress) is "insufficient to make specific recommendations" — the authors explicitly state that trigger avoidance is based on patient self-report, not controlled trials

The guideline is based on studies from Europe, North America, and Australia; results may not generalise to other populations

**What a critical reader would note:**

**No individual-level prediction:** The guideline cannot tell you whether you are in the 95% who respond to ablation or the 5% who do not. It cannot tell you whether caffeine is a trigger for you.

**Confounding in lifestyle studies:** People who drink more caffeine also tend to drink more alcohol, sleep less, and have higher stress — all of which are also triggers. No study has isolated caffeine's effect.

**Short follow-up:** Most ablation studies follow patients for 1–3 years. Long-term recurrence rates (5–10 years) are poorly documented.

**Self-report bias:** Symptom diaries are subjective. People who believe caffeine is a trigger are more likely to report episodes after coffee.

**No placebo control for lifestyle:** You cannot blind someone to whether they are drinking coffee or decaf in a self-experiment, but you can use a double-blind design with a friend preparing the drinks.

**Industry ties:** The guideline authors declared conflicts of interest with Medtronic, Abbott, Biosense Webster, and other device companies. This does not invalidate the recommendations, but it is a source of potential bias toward procedural interventions (ablation) over conservative management.

For someone running their own n=1 experiment to understand and manage their SVT:

### What to test

**Vagal manoeuvres:** Test the modified Valsalva (bear down as if having a bowel movement for 15 seconds, then immediately lie flat and have someone raise your legs to 45 degrees for 15 seconds). Compare to standard Valsalva (sitting up, bearing down for 15 seconds).

**Caffeine:** Test 1 cup of coffee (100 mg caffeine) vs. decaf (5 mg caffeine) at the same time of day, using a double-blind protocol (a friend prepares the drinks and you record which you had after the experiment).

**Alcohol:** Test 1 standard drink (14 g alcohol) vs. a non-alcoholic beer or wine, again double-blind if possible.

**Stress:** Test a 10-minute mindfulness meditation vs. a 10-minute control activity (e.g., reading a neutral article) before a known trigger (e.g., public speaking, a difficult conversation).

**Hydration:** Test drinking 500 ml of water vs. no water when you feel an episode starting.

### Minimum meaningful duration

**Vagal manoeuvres:** Test each manoeuvre 5–10 times over 2–4 weeks (you need enough episodes to compare success rates).

**Caffeine/alcohol:** Test each dose 10–20 times over 2–4 weeks (caffeine has a half-life of 4–6 hours; alcohol has a half-life of 1–2 hours, so you can test daily).

**Stress:** Test daily for 2 weeks (10 sessions of meditation vs. 10 control sessions).

**Hydration:** Test for 2–4 weeks (you need at least 5–10 episodes in each condition).

### What to measure

**Primary outcome:** Episode frequency (number of SVT episodes per day or week). Use a heart rate monitor (e.g., Polar H10 chest strap) to confirm that the episode is SVT (heart rate >150 bpm, sudden onset, sudden offset).

**Secondary outcomes:** Episode duration (minutes from onset to termination), symptom severity (1–10 scale for palpitations, dizziness, chest pain), and termination success (did the manoeuvre stop the episode within 2 minutes?).

**Confounders to measure daily:** Sleep quality (1–10), stress level (1–10), alcohol intake (number of drinks), caffeine intake (mg), exercise (minutes), time of day, menstrual cycle phase (for women).

### Key confounds to control for

**Expectation bias:** You cannot blind yourself to vagal manoeuvres or stress, but you can blind yourself to caffeine/alcohol using a friend to prepare drinks.

**Regression to the mean:** SVT episodes are sporadic. A 2-week period with fewer episodes may be due to chance, not your intervention. Use a run-in period of 2 weeks to establish your baseline frequency.

**Time of day:** SVT episodes are more common in the morning (due to cortisol surge) and after meals (due to vagal withdrawal). Record the time of each episode.

**Menstrual cycle:** Women often have more episodes in the luteal phase (days 14–28 of a 28-day cycle). Track your cycle and compare episodes across phases.

**Exercise:** Intense exercise can trigger SVT in some people. Record your exercise type and intensity (e.g., running at 8 km/h for 30 minutes).

**Medications:** Beta-blockers, calcium channel blockers, and antiarrhythmic drugs will suppress episodes and confound your results